Entering 2026, the financial footprint of the immunotherapy sector has expanded to unprecedented levels, firmly establishing it as the most valuable segment within the oncology drug market. Recent financial reports indicate that the global valuation for these therapies is now exceeding $66 billion, with projections suggesting a trajectory toward $237 billion by the early 2030s. This...